Publication:
Biologic treatments in Behcet's disease

Simple item page
dc.contributor.authorALİBAZ ÖNER, FATMA
dc.contributor.authorsAlibaz-Oner, Fatma; Direskeneli, Haner
dc.date.accessioned2022-03-10T11:39:07Z
dc.date.available2022-03-10T11:39:07Z
dc.date.issued2021-11-22
dc.description.abstractBehcet's disease (BD) significantly increases morbidity and mortality, especially in young men. While vascular involvement is the most frequent cause of mortality, ocular involvement, which can cause visual loss, is the most important cause of morbidity in BD. Immunosuppressive treatment is the mainstay for major organ involvement. However, despite optimal immunosuppressive treatment, relapses and disease-related damage develop in a subgroup of patients, especially among those with ocular or vascular involvement. With the recent understanding of the immuno-pathogenesis, biologic treatments targeting potential pathogenic cells, cytokines or pathways are better optimized in BD. Data from large series showed that tumor necrosis factor-alpha inhibitors and interferon-alpha are effective and safe treatment options for the treatment of refractory and major organ involvement, such as ocular, neurologic, vascular, and gastrointestinal. Anakinra and ustekinumab also seem to be promising agents for refractory mucocutaneous disease. IL-1 inhibitors and tocilizumab may be alternatives for the treatment of patients with refractory eye involvement. Still, randomized controlled trials of biologic agents, especially for the treatment of major organ involvement, are insufficient, and further prospective, long-term follow-up studies are needed to clarify the efficacy, safety, and optimal treatment duration of biologic agents in BD.
dc.identifier.doi10.5152/eurjrheum.2020.20138
dc.identifier.eissn2148-4279
dc.identifier.issn2147-9720
dc.identifier.pubmed33687828
dc.identifier.urihttps://hdl.handle.net/11424/219834
dc.identifier.wosWOS:000723215400007
dc.language.isoeng
dc.publisherAVES
dc.relation.ispartofEUROPEAN JOURNAL OF RHEUMATOLOGY
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBehcet's disease
dc.subjecttreatment
dc.subjectbiologic agents
dc.subjectGENOME-WIDE ASSOCIATION
dc.subjectLONG-TERM EFFICACY
dc.subjectREFRACTORY NEURO-BEHCET
dc.subjectREGULATORY T-CELLS
dc.subjectMHC CLASS-I
dc.subjectINTERFERON-ALPHA
dc.subjectREMISSION INDUCTION
dc.subjectSEVERE UVEITIS
dc.subjectOPEN-LABEL
dc.subjectINFLIXIMAB TREATMENT
dc.titleBiologic treatments in Behcet's disease
dc.typereview
dspace.entity.typePublication
local.avesis.id867bc0eb-bc36-4ecc-a5a5-c34fda50fd69
local.import.packageSS4
local.indexed.atWOS
local.indexed.atPUBMED
local.indexed.atTRDIZIN
local.journal.numberofpages6
oaire.citation.endPage222
oaire.citation.issue4
oaire.citation.startPage217
oaire.citation.titleEUROPEAN JOURNAL OF RHEUMATOLOGY
oaire.citation.volume8
relation.isAuthorOfPublicatione995a136-8c56-4192-bebe-fe522b567ef1
relation.isAuthorOfPublication.latestForDiscoverye995a136-8c56-4192-bebe-fe522b567ef1

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Division of Rheumatology, Department of Internal Medicine, Marmara University School of Medicine, İstanbul, Turkey et al. - 2021 - Biologic treatments in Behçet’s disease.pdf
Size:
572.44 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs